What is Roth Capital's Forecast for ZVRA FY2029 Earnings?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Equities research analysts at Roth Capital cut their FY2029 earnings per share (EPS) estimates for Zevra Therapeutics in a note issued to investors on Tuesday, March 11th. Roth Capital analyst J. Aschoff now anticipates that the company will earn $2.05 per share for the year, down from their previous estimate of $2.26. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.95) per share.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.28). The company had revenue of $12.00 million during the quarter, compared to the consensus estimate of $8.93 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%.

Several other equities analysts also recently commented on the stock. Guggenheim increased their target price on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday. Canaccord Genuity Group increased their target price on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a research note on Thursday. Citigroup reiterated an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 target price on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Finally, HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Zevra Therapeutics in a research note on Thursday. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Zevra Therapeutics presently has an average rating of "Buy" and a consensus target price of $22.14.

Remove Ads

Zevra Therapeutics Stock Up 0.5 %

Shares of NASDAQ:ZVRA traded up $0.04 during midday trading on Thursday, hitting $8.35. 351,869 shares of the stock were exchanged, compared to its average volume of 574,095. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. Zevra Therapeutics has a 52-week low of $4.20 and a 52-week high of $9.76. The business's fifty day simple moving average is $7.93 and its two-hundred day simple moving average is $8.16. The company has a market capitalization of $451.87 million, a PE ratio of -4.24 and a beta of 1.98.

Institutional Trading of Zevra Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ZVRA. BNP Paribas Financial Markets bought a new position in Zevra Therapeutics in the 4th quarter valued at approximately $53,000. China Universal Asset Management Co. Ltd. bought a new position in Zevra Therapeutics during the fourth quarter worth $94,000. XTX Topco Ltd bought a new position in Zevra Therapeutics during the third quarter worth $94,000. Intech Investment Management LLC bought a new position in Zevra Therapeutics during the third quarter worth $95,000. Finally, Squarepoint Ops LLC raised its stake in Zevra Therapeutics by 36.1% during the fourth quarter. Squarepoint Ops LLC now owns 16,534 shares of the company's stock worth $138,000 after buying an additional 4,384 shares during the last quarter. Institutional investors own 35.03% of the company's stock.

Insider Transactions at Zevra Therapeutics

In other Zevra Therapeutics news, CFO R. Laduane Clifton sold 11,000 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $86,460.00. Following the transaction, the chief financial officer now owns 51,361 shares in the company, valued at $403,697.46. This represents a 17.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Joshua Schafer sold 10,500 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $82,530.00. Following the sale, the executive vice president now directly owns 29,486 shares of the company's stock, valued at approximately $231,759.96. This trade represents a 26.26 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 85,773 shares of company stock worth $674,176 in the last ninety days. Insiders own 2.40% of the company's stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.